Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.

Pharmacogenomics - 1 May 2012

Andersson Marine L, Eliasson Erik, Lindh Jonatan D

Abstract excerpt

BACKGROUND: Simvastatin interacts with warfarin, but the strength of the interaction varies between individual patients, indicating a genetic predisposition. PATIENTS & METHODS: The influence of the CYP2C9*2 and CYP2C9*3 polymorphisms on the interaction between simvastatin and warfarin was analyzed in data from 1132 patients. RESULTS: Simvastatin use reduced warfarin dose requirements by 29% in carriers of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dose-Response Relationship, Drug

Share to Drug Interactions

Share to Hypolipidemic Agents

Share to Simvastatin

Share to Warfarin

Source

Identifiers

PMID: 22594507
DOI: 10.2217/pgs.12.40

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele.PMID 22594507Read ↗

Association of cytochromes P450 3A4*22 and 3A5*3 genotypes and polymorphism with response to simvastatin in hypercholesterolemia patients.Semantic proximity Read ↗

Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.Semantic proximity Read ↗

CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.Semantic proximity Read ↗

CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.Semantic proximity Read ↗

Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population.Semantic proximity Read ↗

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.Semantic proximity Read ↗

Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.Semantic proximity Read ↗

Pharmacogenetics of warfarin elimination and its clinical implications.Semantic proximity Read ↗

Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants.Semantic proximity Read ↗

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.Semantic proximity Read ↗

Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.Semantic proximity Read ↗

CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.